Debbie Hicks
Newcastle University
H-index: 22
Europe-United Kingdom
Top articles of Debbie Hicks
The clinical significance of sub-total surgical resection in childhood medulloblastoma: a multi-cohort analysis of 1100 patients
Eclinicalmedicine
2024/3/1
Metabolite profiles of medulloblastoma for rapid and non-invasive detection of molecular disease groups
Ebiomedicine
2024/2/1
Molecular characterisation defines clinically-actionable heterogeneity within Group 4 medulloblastoma and improves disease risk-stratification
Acta neuropathologica
2023/5
Single-cell DNA sequencing identifies risk-associated clonal complexity and evolutionary trajectories in childhood medulloblastoma development
Acta neuropathologica
2022/9
Medulloblastoma group 3 and 4 tumors comprise a clinically and biologically significant expression continuum reflecting human cerebellar development
Cell reports
2022/8/2
PATH-06. Molecular subgrouping of medulloblastoma via low-depth whole genome bisulfite sequencing
Neuro-Oncology
2022/6
MEDB-31. THE CLINICAL SIGNIFICANCE OF EXTENT OF RESECTION IN MEDULLOBLASTOMA
Neuro-Oncology
2022/6
Simon Davies
H-Index: 38
Debbie Hicks
H-Index: 16
MOLECULAR CHARACTERISATION OF GROUP 4 MEDULLOBLASTOMA IMPROVES RISK-STRATIFICATION AND ITS BIOLOGICAL UNDERSTANDING
2022/6/1
QOL-28. Clinico-molecular correlates of quality of survival and neurocognitive outcomes in medulloblastoma; a meta-analysis of the SIOP-UKCCSG-PNET3 and HIT-SIOP-PNET4 trials
Neuro-Oncology
2022/6/1
MEDB-65. Molecular subclassification of a national cohort of pediatric medulloblastoma based on methylation profile
Neuro-Oncology
2022/6/1
Debbie Hicks
H-Index: 16
Emergence and maintenance of actionable genetic drivers at medulloblastoma relapse
Neuro-oncology
2022/1/1
Advanced molecular pathology for rare tumours: A national feasibility study and model for centralised medulloblastoma diagnostics
Neuropathology and Applied Neurobiology
2021/10
OMIC-06. Molecular subgrouping of medulloblastoma via low-depth Whole Genome Bisulfite Sequencing.
Neuro-Oncology
2021/6/1
EMBR-25. Genome-wide genetic and epigenetic assessment of group 4 Medulloblastoma for improved, biomarker driven, prognostication and risk-stratification
Neuro-oncology
2021/6/1
The molecular landscape and associated clinical experience in infant medulloblastoma: prognostic significance of second‐generation subtypes
Neuropathology and Applied Neurobiology
2021/2
MBRS-60. THE ACTIONABLE GENOMIC LANDSCAPE OF RELAPSED MEDULLOBLASTOMA IS DEFINED BY MAINTENANCE AND ACQUISITION OF DRIVER EVENTS
Neuro-oncology
2020/12/1
Stacey Richardson
H-Index: 1
Debbie Hicks
H-Index: 16
Daniel Williamson
H-Index: 13
Simon Bailey
H-Index: 13
MBRS-44. Time, pattern and outcome of medulloblastoma relapse are associated with tumour biology at diagnosis and upfront therapy: a cohort study
Neuro-oncology
2020/12/1
QOL-17. Biological correlates of quality of survival and neurocognitive outcomes in medulloblastoma; a meta-analysis of the SIOP-UKCCSG-PNET3 and HIT-SIOP-PNET4 trials
Neuro-Oncology
2020/12/1
Time, pattern, and outcome of medulloblastoma relapse and their association with tumour biology at diagnosis and therapy: a multicentre cohort study
The Lancet Child & Adolescent Health
2020/12/1
Pediatric pan-central nervous system tumor analysis of immune-cell infiltration identifies correlates of antitumor immunity
Nature communications
2020/8/28
